Áttétes emlőrák: vizsgálatok itt: Olaszország
70 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 10.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Where
- Bergamo, Bologna, Genova, Milan, Monza, Novara, Torrette
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- ALX Oncology Inc.
See details and how to joinNCT07007559 - 3. fázisTaking peopleBGB-43395 in Combination with Letrozole versus CDK4/6i with Letrozole for Patients with Previously Untreated Advanced or Metastatic HR+/HER2- Breast Cancer
- Where
- Ancona, Bergamo, Genoa, Milan, Monza, Padova, Rome
- Életkor
- 18 év and over
- People
- 233 worldwide
- Run by
- BeOne Medicines I GmbH
See details and how to joinNCT07492641 · EU 2025-523960-19-00 - 1/2. fázisTaking peopleBeamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Where
- Ancona, Candiolo (TO), Meldola (FC), Milan, Misterbianco (CT), Naples, Rozzano
- Életkor
- 18 év and over
- People
- 910 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06324357 - 3. fázisTaking peoplePhase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Where
- Ancona, Brescia, Candiolo, Caserta, Empoli, Ferrara, Florence, Leghorn, Meldola, Milan, Misterbianco, Padova, Palermo, Parma, Pavia, Rome, Terni
- Életkor
- 18 év and over
- People
- 540 worldwide
- Run by
- Relay Therapeutics, Inc.
See details and how to joinNCT06982521 · EU 2025-523083-21-00 - 2/3. fázisTaking peopleRO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
- Where
- Aviano, Bergamo, Brescia, Meldola, Milan, Misterbianco (CT), Modena, Naples, Padova, Parma, Rome, Rozzano
- Életkor
- 18 év and over
- People
- 650 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07413939 · EU 2025-524498-17-00 - 3. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Where
- Bergamo, Bologna, Bolzano, Caserta, Meldola, Milan, Misterbianco, Modena, Naples, Novara, Pisa, Rome, Rozzano, Terni, Tricase
- Életkor
- 18 év and over
- People
- 450 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06790693 · EU 2024-516162-11-00 - 3. fázisTaking peopleA Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Where
- Bergamo, Bologna, Florence, Genova, Meldola, Milan, Misterbianco, Monza, Naples, Padova, Roma
- Életkor
- 18 év and over
- People
- 800 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07174336 · EU 2025-522791-92-00 - 3. fázisTaking peopleA Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Where
- Bergamo, Milan, Naples, Roma
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07060807 · EU 2025-520582-51-00 - 2. fázisTaking peopleA Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
- Where
- Bergamo, Meldola, Milan, Naples, Rome
- Életkor
- 18 év and over
- People
- 80 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07405801 · EU 2025-523013-28-00 - 1. fázisTaking peopleStudy of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
- Where
- Ancona
- Életkor
- 18 év and over
- People
- 194 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07604571 - 3. fázisTaking peopleA Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment (EmpowHER 303)
- Where
- Ancona, Aviano, Bergamo, Bologna, Busto Arsizio, Catania, Genoa, Milan, Modena, Monza, Naples, Padova, Pavia, Rivoli, Rome, Rozzano
- Életkor
- 18 év and over
- People
- 264 worldwide
- Run by
- Jazz Pharmaceuticals Ireland Limited
See details and how to joinNCT06435429 · EU 2023-508960-31-00 - 3. fázisTaking peopleSaruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- Where
- Bergamo, Bologna, Milan, Naples, Padova, Reggio Emilia, Rome, Rozzano
- Életkor
- 18 év and over
- People
- 788 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06380751 · EU 2023-504180-16-00 - 3. fázisTaking peopleEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Where
- Ancona, Aviano, Candiolo, Meldola, Milan, Misterbianco, Modena, Naples, Padova, Parma, Pavia, Rome
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- LeonaBio
See details and how to joinNCT05696626 · EU 2023-503708-10-00 - 3. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
- Where
- Caserta, Meldola, Milan, Trento
- Életkor
- 18 év and over
- People
- 420 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05646862 · EU 2022-502322-41-00 - 1/2. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Candiolo, Milan, Naples, Rome, Rozzano
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - 1. fázisNot yet taking people in OlaszországA phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
- Where
- Milan, Naples
- Életkor
- 18 év and over
- People
- 64 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-518348-19-00 · EU 2024-518348-19-00 - 1. fázisTaking peopleA clinical trial to learn about the effects of IEV407 when given alone or with endocrine therapy in people with advanced breast cancer
- Where
- Ancona
- Életkor
- 18 év and over
- People
- 40 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-522707-26-00 · EU 2025-522707-26-00 - 2. fázisTaking peopleEvaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
- Where
- Milan
- Életkor
- 18 év and over
- People
- 90 worldwide
- Run by
- Delcath Systems Inc.
See details and how to joinNCT06875128 · EU 2025-521966-91-00 - 3. fázisTaking peopleA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Where
- Bologna, Leghorn, Meldola, Milan, Modena, Monza, Naples, Rome
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Pfizer
See details and how to joinNCT07062965 · EU 2025-520566-22-00 - 3. fázisTaking peopleA Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Where
- Aviano, Bergamo, Genova, Milan, Naples
- Életkor
- 18 év to 130 év
- People
- 150 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07647328 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Where
- Bagno A Ripoli, Meldola, Milan, Monza, Novara, Palermo, Rome, Verona
- Életkor
- 18 év and over
- People
- 230 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05894239 · EU 2022-502046-28-00 - 1/2. fázisTaking peopleA Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- Where
- Bologna, Genoa, Milan, Naples, Rome
- Életkor
- 18 év and over
- People
- 380 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT06827236 · EU 2024-517979-20-00 - 3. fázisTaking peopleA Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Where
- Aviano, Bologna, Genova, Meldola, Milan, Roma, Rozzano
- Életkor
- 18 év and over
- People
- 1200 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06312176 · EU 2023-504918-29-00 - 1/2. fázisTaking peopleTo compare the Safety and activity of GDC-4198 Alone and in Combination with Giredestrant against Abemaciclib and Giredestrant in Participants with Breast Cancer
- Where
- Bergamo, Bologna, Brescia, Meldola, Milan
- Életkor
- 18 év and over
- People
- 73 worldwide
- Run by
- Genentech Inc.
See details and how to join2025-521128-31-00 · EU 2025-521128-31-00 - 3. fázisTaking peoplePhase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- Where
- Fano, Genoa, Meldola, Milan, Modena, Naples, Parma, Pavia, Prato, Ravenna, Rome, Rozzano, Terni, Verona
- Életkor
- 18 év and over
- People
- 1180 worldwide
- Run by
- Celcuity Inc
See details and how to joinNCT06757634 · EU 2024-518933-28-01